Literature DB >> 16431343

S100A4 (Mts1): is there any relation to the pathogenesis of rheumatoid arthritis?

Ladislav Senolt1, Mariam Grigorian, Eugene Lukanidin, Beat A Michel, Renate E Gay, Steffen Gay, Karel Pavelka, Michel Neidhart.   

Abstract

S100A4 (Mts1) belongs to the S100 family of calcium binding proteins, which are involved in diverse biological regulatory activities. An association between S100A4 and tumor progression has been demonstrated in several studies. S100A4 binds to distinct intracellular target proteins and regulates specific functions involved in tumor progression such as cell motility, proliferation and apoptosis as well as remodelling of the extracellular matrix. Once released from the tumor or tumor-activated stromal cells, it may influence certain functions of target cells towards a more aggressive phenotype. Extracellular S100A4 has been demonstrated to contribute to angiogenesis and the increased production of matrix-degrading enzymes by both endothelial and tumor cells. Moreover, S100A4 might be responsible for TCRgammadelta T-cell mediated lysis and negative regulation of matrix mineralization. Increased expression of S100A4 mRNA has recently been found in proliferating rheumatoid arthritis synovial fibroblasts and synovial tissues from rheumatoid arthritis patients. Synovial hyperplasia in rheumatoid arthritis consists of inflammatory cells and activated synovial lining cells which contribute to the progressive destruction of the joints during the disease. Since several phenomena are similar between rheumatoid arthritis and malignant tumors it can be hypothesized that S100A4 contributes to the invasive and tumor-like behavior of rheumatoid arthritis synovium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16431343     DOI: 10.1016/j.autrev.2005.09.010

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  8 in total

1.  Analyses of differential proteome of human synovial fibroblasts obtained from arthritis.

Authors:  Gan-Ping Bo; Li-Na Zhou; Wei-Feng He; Gao-Xing Luo; Xiong-Fei Jia; Cheng-Jun Gan; Guang-Xing Chen; Yong-Fei Fang; Peter Mose Larsen; Jun Wu
Journal:  Clin Rheumatol       Date:  2008-09-20       Impact factor: 2.980

2.  Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis.

Authors:  Ryan A Hlady; Slavomira Novakova; Jana Opavska; David Klinkebiel; Staci L Peters; Juraj Bies; Jay Hannah; Javeed Iqbal; Kristi M Anderson; Hollie M Siebler; Lynette M Smith; Timothy C Greiner; Dhundy Bastola; Shantaram Joshi; Oksana Lockridge; Melanie A Simpson; Dean W Felsher; Kay-Uwe Wagner; Wing C Chan; Judith K Christman; Rene Opavsky
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

Review 3.  Surfactant protein DNA methylation: a new entrant in the field of lung cancer diagnostics? (Review).

Authors:  Mudit Vaid; Joanna Floros
Journal:  Oncol Rep       Date:  2009-01       Impact factor: 3.906

Review 4.  S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases?

Authors:  Mikael Schneider; Jakob L Hansen; Søren P Sheikh
Journal:  J Mol Med (Berl)       Date:  2008-03-06       Impact factor: 4.599

5.  Gene expression profiling of cutaneous wound healing.

Authors:  Kavita Deonarine; Monica C Panelli; Mitchell E Stashower; Ping Jin; Kina Smith; Herbert B Slade; Christopher Norwood; Ena Wang; Francesco M Marincola; David F Stroncek
Journal:  J Transl Med       Date:  2007-02-21       Impact factor: 5.531

6.  Single-cell analysis reveals heterogeneity of juvenile idiopathic arthritis fibroblast-like synoviocytes with implications for disease subtype.

Authors:  Megan M Simonds; Kathleen E Sullivan; AnneMarie C Brescia
Journal:  Arthritis Res Ther       Date:  2022-09-27       Impact factor: 5.606

7.  S100 A and B expression in normal and inflamed human limbus.

Authors:  Mario Nubile; Manuela Lanzini; Roberta Calienno; Rodolfo Mastropasqua; Claudia Curcio; Alessandra Mastropasqua; Luca Agnifili; Leonardo Mastropasqua
Journal:  Mol Vis       Date:  2013-01-28       Impact factor: 2.367

8.  Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor.

Authors:  Arsheed A Ganaie; Adrian P Mansini; Tabish Hussain; Arpit Rao; Hifzur R Siddique; Ashraf Shabaneh; Marina G Ferrari; Paari Murugan; Jörg Klingelhöfer; Jinhua Wang; Noona Ambartsumian; Christopher A Warlick; Badrinath R Konety; Mohammad Saleem
Journal:  Mol Cancer Ther       Date:  2020-09-30       Impact factor: 6.009

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.